Data

Data Bridge Market Research analyses that the Circulating Tumor DNA (Ctdna) Market was USD 1234.58 million in 2021, would rocket up to USD 4335.17 million by 2029, and is expected to undergo a CAGR of 17% during the forecast period of 2022-2029. Industry Analysis Nucleated cells lacking CD45 and expressing cytokeratin were classified as circulating tumor cells. The use of circulating tumor DNA diagnostics to identify cancer reduces the requirement for sample tumor tissue, such as tumor biopsy. Tumor DNA diagnostics in the blood are also used to guide tumor-specific treatment. This strategy aids the clinician in determining the most appropriate cancer treatment option. Circulating tumor DNA (ctDNA) is a type of DNA produced by malignant and tumor cells that spread throughout the body. This occurs when a tumor grows and cells die, only to be replaced by a new one, releasing the dead cells into the bloodstream. This DNA are commonly found in  leiomyosarcoma  patients. Ur...